FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 326:363-367 February 6, 1992 Number 6 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. An association between polymyositis and cancer was first proposed in 1916, but the existence of the association has been disputed. An association between dermatomyositis and cancer is better accepted, but its magnitude is not known. METHODS. We undertook a study to provide accurate estimates of the risk of cancer in patients with dermatomyositis or polymyositis. We studied the incidence of cancer and the rate of mortality from cancer in a population-based cohort of 788 patients with dermatomyositis or polymyositis in Sweden from 1963 through 1983. The results were compared with those for the general population. RESULTS. Among the 396 patients with polymyositis, 42 cancers were diagnosed at the same time or after polymyositis was diagnosed in 37 patients (9 percent). The relative risk of cancer was 1.8 (95 percent confidence interval, 1.1 to 2.7) in the male patients and 1.7 (95 percent confidence interval, 1.0 to 2.5) in the female patients. Eighty-four males and 85 females died, and in 24 of these cases (14 percent) cancer was the principal cause of death. The mortality ratio (the rate of mortality from cancer in these patients as compared with that in the general population) was 0.90 (95 percent confidence interval, 0.6 to 1.4). Among the 392 patients with dermatomyositis, 61 cancers were diagnosed at the same time or after dermatomyositis was diagnosed in 59 patients (15 percent). The relative risk of cancer was 2.4 (95 percent confidence interval, 1.6 to 3.6) in the male patients and 3.4 (95 percent confidence interval, 2.4 to 4.7) in the female patients. Fifty-seven males and 110 females died, and in 67 of these cases (40 percent) cancer was the principal cause of death (mortality ratio, 3.8; 95 percent confidence interval, 2.9 to 4.8). CONCLUSIONS. The risk of cancer is increased in patients with polymyositis or dermatomyositis. In patients with dermatomyositis there is also a higher rate of mortality from cancer.

Source Information

Department of Dermatology, Karolinska Hospital, Stockholm, Sweden.

This article has been cited by other articles:

• ANTIOCHOS, B. B., BROWN, L. A., LI, Z., TOSTESON, T. D., WORTMANN, R. L., RIGBY, W. F.C. (2009). Malignancy Is Associated with Dermatomyositis But Not Polymyositis in Northern New England, USA. The Journal of Rheumatology 36: 2704-2710 [Abstract] [Full Text]  
• Amato, A A, Barohn, R J (2009). Evaluation and treatment of inflammatory myopathies. J. Neurol. Neurosurg. Psychiatry 80: 1060-1068 [Abstract] [Full Text]  
• Chinoy, H., Fertig, N., Oddis, C. V, Ollier, W. E R, Cooper, R. G (2007). The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66: 1345-1349 [Abstract] [Full Text]  
• Smedby, K. E., Baecklund, E., Askling, J. (2006). Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics.. Cancer Epidemiol. Biomarkers Prev. 15: 2069-2077 [Abstract] [Full Text]  
• Gabrilovich, M., Raza, M., Dolan, S., Raza, T. (2006). Paraneoplastic Polymyositis Associated With Squamous Cell Carcinoma of the Lung. Chest 129: 1721-1723 [Abstract] [Full Text]  
• Polisson, R. P., Crocker, J. T., Mueller, P. R., Harris, N. L., Duncan, L. M. (2005). Case 29-2005 - A 68-Year-Old Man with Periorbital Swelling, Rash, and Weakness. NEJM 353: 1275-1284 [Full Text]  
• Amoura, Z., Duhaut, P., Huong, D. L. T., Wechsler, B., Costedoat-Chalumeau, N., Frances, C., Cacoub, P., Papo, T., Cormont, S., Touitou, Y., Grenier, P., Valeyre, D., Piette, J.-C. (2005). Tumor Antigen Markers for the Detection of Solid Cancers in Inflammatory Myopathies. Cancer Epidemiol. Biomarkers Prev. 14: 1279-1282 [Abstract] [Full Text]  
• Casciola-Rosen, L., Nagaraju, K., Plotz, P., Wang, K., Levine, S., Gabrielson, E., Corse, A., Rosen, A. (2005). Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. JEM 201: 591-601 [Abstract] [Full Text]  
• Mehta, V., Swaroop, V. S. (2004). 70-Year-Old Woman With Rash and Muscle Weakness. Mayo Clin Proc. 79: 923-926  
• Yaqub, S., Moder, K. G., Lacy, M. Q. (2004). Severe, Reversible Pulmonary Hypertension in a Patient With Monoclonal Gammopathy and Features of Dermatomyositis. Mayo Clin Proc. 79: 687-689 [Abstract]  
• Watkins, J., Farzaneh-Far, R., Tahir, H., Wykes, F., Studdy, P. R., Beynon, H. L. C. (2004). Jo-1 syndrome with associated poorly differentiated adenocarcinoma. Rheumatology (Oxford) 43: 389-390 [Full Text]  
• Shimono, Y., Murakami, H., Kawai, K., Wade, P. A., Shimokata, K., Takahashi, M. (2003). Mi-2{beta} Associates with BRG1 and RET Finger Protein at the Distinct Regions with Transcriptional Activating and Repressing Abilities. J. Biol. Chem. 278: 51638-51645 [Abstract] [Full Text]  
• Ragnarsson, O, Grondal, G, Steinsson, K (2003). Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus 12: 687-691 [Abstract]  
• (2003). A bed bound patient. Postgrad. Med. J. 79: 421-423 [Full Text]  
• Sparsa, A., Liozon, E., Herrmann, F., Ly, K., Lebrun, V., Soria, P., Loustaud-Ratti, V., Bouyssou-Gauthier, M.-L., Boulinguez, S., Bedane, C., Jauberteau, M.-O., Vidal, E., Bonnetblanc, J.-M. (2002). Routine vs Extensive Malignancy Search for Adult Dermatomyositis and Polymyositis: A Study of 40 Patients. Arch Dermatol 138: 885-890 [Abstract] [Full Text]  
• Callen, J. P. (2002). When and How Should the Patient With Dermatomyositis or Amyopathic Dermatomyositis Be Assessed for Possible Cancer?. Arch Dermatol 138: 969-971 [Full Text]  
• Yiannopoulos, G, Ravazoula, P, Meimaris, N, Stavropoulos, M, Andonopoulos, A P (2002). Dermatomyositis in a patient with adenocarcinoma of the gall bladder. Ann Rheum Dis 61: 663-664 [Full Text]  
• Bouros, D., Hatzakis, K., Labrakis, H., Zeibecoglou, K. (2002). Association of Malignancy With Diseases Causing Interstitial Pulmonary Changes*. Chest 121: 1278-1289 [Abstract] [Full Text]  
• Raffel, G. D., Gravallese, E. M., Schwab, P., Joseph, J. T., Cannistra, S. A. (2001). Diagnostic Dilemmas in Oncology: Case 2. Dermatomyositis and Ovarian Cancer. JCO 19: 4341-4343 [Full Text]  
• Rockall, A G, Rickards, D, Shaw, P J (2001). Imaging of the pulmonary manifestations of systemic disease. Postgrad. Med. J. 77: 621-638 [Full Text]  
• Buchbinder, R., Forbes, A., Hall, S., Dennett, X., Giles, G. (2001). Incidence of Malignant Disease in Biopsy-Proven Inflammatory Myopathy: A Population-Based Cohort Study. ANN INTERN MED 134: 1087-1095 [Abstract] [Full Text]  
• Ramsey-Goldman, R, Clarke, A E (2001). Double trouble: are lupus and malignancy associated?. Lupus 10: 388-391  
• Abu-Shakra, M, Buskila, D, Ehrenfeld, M, Conrad, K, Shoenfeld, Y (2001). Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 60: 433-441 [Abstract] [Full Text]  
• Till, S. H, Jones, A. C (1998). Dermatomyositis---how far to go!. Ann Rheum Dis 57: 198-200 [Full Text]  
• Cosnes, A., Amaudric, F., Gherardi, R., Verroust, J., Wechsler, J., Revuz, J., Roujeau, J. C. (1995). Dermatomyositis Without Muscle Weakness: Long-term Follow-up of 12 Patients Without Systemic Corticosteroids. Arch Dermatol 131: 1381-1385 [Abstract]  
• Kagen, L. J. (1995). Amyopathic Dermatomyositis. Arch Dermatol 131: 1458-1459 [Abstract]